{
    "clinical_study": {
        "@rank": "148068", 
        "brief_summary": {
            "textblock": "This study is a Phase 1, dose escalation, first-in-human study designed primarily to\n      evaluate the safety of the purified plant-derived Pfs25 VLP combined with Alhydrogel\n      adjuvant"
        }, 
        "brief_title": "Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Malaria", 
        "condition_browse": {
            "mesh_term": "Malaria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or non-pregnant, non-lactating female aged 18 - 50 years inclusive\n\n          -  Able to give written informed consent obtained prior to screening\n\n          -  Healthy, as determined by medical history, physical examination, vital signs,  and\n             clinical safety laboratory examinations at baseline\n\n          -  Women of childbearing potential must have a negative urine pregnancy test within 24\n             hours preceding receipt of each dose.\n\n          -  Females should fulfill one of the following criteria:\n\n               1. At least one year post-menopausal\n\n               2. Surgically sterile\n\n               3. Willing to use oral, implantable, transdermal or injectable  contraceptives for\n                  30 days prior to first vaccination and then for the study duration\n\n               4. Willing to abstain from sexual intercourse or use another reliable form of\n                  contraception approved by the Investigator (e.g., intrauterine device (IUD),\n                  female condom, diaphragm with spermicide, cervical cap, use of condom by the\n                  sexual partner or a sterile sexual partner) for 30 days prior to first\n                  vaccination through 9 months after third vaccination\n\n          -  Comprehension of the study requirements, as demonstrated by achieving a score of at\n             least 80% correct on a short multiple-choice quiz.\n\n               -  Individuals who fail to achieve a passing score on the initial comprehension\n                  assessment will be given the opportunity to retest after a review of protocol\n                  information.\n\n               -  Individuals who fail the comprehension assessment for the second time will not\n                  be enrolled.\n\n          -  Available and able to participate in all planned study visits and procedures.\n\n        Exclusion Criteria:\n\n          -  History of malaria or previous receipt of an investigational malaria vaccine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013687", 
            "org_study_id": "FhCMB Pfs25-001"
        }, 
        "intervention": {
            "intervention_name": "Pfs25 VLP- FhCMB", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "contact": {
                "last_name": "Stephan Bart, MD", 
                "phone": "240-238-4953"
            }, 
            "facility": {
                "address": {
                    "city": "Rockville", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20850"
                }, 
                "name": "Accelovance"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "No", 
            "time_frame": "420 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013687"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fraunhofer, Center for Molecular Biotechnology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fraunhofer, Center for Molecular Biotechnology", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}